Celularity Inc SEC filings CELU
Celularity Inc has 560 filings in SEC EDGAR's recent list, going back to Nov 5, 2018. Its latest annual report, Form 10-K, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 20, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | Jan 8, 2026 | — |
| S-1 | Registration statement | Dec 31, 2025 | — |
| 424B3 | Prospectus | Dec 30, 2025 | — |
| S-1 | Registration statement | Dec 19, 2025 | — |
| S-8 | Employee stock plan registration | Nov 7, 2025 | — |
| FWP | Free writing prospectus | Feb 13, 2025 | — |
| S-1/A | Amended registration statement | Feb 13, 2025 | — |
| S-1 | Registration statement | Jan 30, 2025 | — |
| 424B5 | Prospectus supplement | Jul 28, 2023 | — |
| 424B3 | Prospectus | Jun 2, 2023 | — |
| S-3 | Shelf registration | May 25, 2023 | — |
| 424B5 | Prospectus supplement | Apr 7, 2023 | — |
| 424B5 | Prospectus supplement | Sep 15, 2022 | — |
| 424B5 | Prospectus supplement | Sep 8, 2022 | — |
| 424B3 | Prospectus | Aug 24, 2022 | — |
| 424B3 | Prospectus | Aug 24, 2022 | — |
| S-3 | Shelf registration | Aug 11, 2022 | — |
| POS AM | Filing | Aug 11, 2022 | — |
| POS AM | Filing | Aug 11, 2022 | — |
| S-8 | Employee stock plan registration | Aug 11, 2022 | — |
| 424B3 | Prospectus | Aug 10, 2022 | — |
| 424B3 | Prospectus | Aug 10, 2022 | — |
| 424B3 | Prospectus | Jul 20, 2022 | — |
| 424B3 | Prospectus | Jul 20, 2022 | — |
| 424B3 | Prospectus | Jul 14, 2022 | — |
| 424B3 | Prospectus | Jul 14, 2022 | — |
| 424B3 | Prospectus | Jun 21, 2022 | — |
| 424B3 | Prospectus | Jun 21, 2022 | — |
| 424B3 | Prospectus | Jun 3, 2022 | — |
| 424B3 | Prospectus | Jun 3, 2022 | — |
| 424B3 | Prospectus | Jun 1, 2022 | — |
| S-1 | Registration statement | May 25, 2022 | — |
| 424B3 | Prospectus | May 20, 2022 | — |
| 424B3 | Prospectus | May 17, 2022 | — |
| S-1/A | Amended registration statement | May 11, 2022 | — |
| 424B3 | Prospectus | May 3, 2022 | — |
| 424B3 | Prospectus | May 3, 2022 | — |
| S-1 | Registration statement | Apr 29, 2022 | — |
| POS AM | Filing | Apr 4, 2022 | — |
| 424B3 | Prospectus | Mar 16, 2022 | — |
| 424B3 | Prospectus | Mar 1, 2022 | — |
| 424B3 | Prospectus | Feb 16, 2022 | — |
| 424B3 | Prospectus | Jan 18, 2022 | — |
| 424B3 | Prospectus | Dec 28, 2021 | — |
| 424B3 | Prospectus | Dec 17, 2021 | — |
| 424B3 | Prospectus | Nov 12, 2021 | — |
| S-8 | Employee stock plan registration | Oct 4, 2021 | — |
| 424B3 | Prospectus | Sep 17, 2021 | — |
| 424B3 | Prospectus | Aug 20, 2021 | — |
| 424B3 | Prospectus | Aug 20, 2021 | — |
| 424B3 | Prospectus | Aug 20, 2021 | — |
| 424B3 | Prospectus | Aug 12, 2021 | — |
| S-1 | Registration statement | Aug 6, 2021 | — |
| 424B3 | Prospectus | Jun 25, 2021 | — |
| S-4/A | Registration statement | Jun 22, 2021 | — |
| S-4/A | Registration statement | Jun 7, 2021 | — |
| S-4/A | Registration statement | Apr 23, 2021 | — |
| S-4/A | Registration statement | Mar 29, 2021 | — |
| S-4 | Registration for a merger or exchange | Jan 25, 2021 | — |
| 424B4 | Prospectus | May 21, 2019 | — |
| S-1/A | Amended registration statement | May 13, 2019 | — |
| S-1 | Registration statement | Apr 26, 2019 | — |
Showing 62 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CELU (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Florham Park, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1752828
- Former names
- GX Acquisition Corp. (until Jul 19, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.